← Eichor
Study identifier: NCT05656105 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection

Condition: SARS CoV-2 Post-Acute Sequelae  ·  Sponsor: University of Alabama at Birmingham

PhaseEARLY_Phase 1
Planned participants60
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersYes

About this study

This clinical imaging study will use the small molecule translocator protein (TSPO) ligand, Fluorodeoxyglucose(18F)-labeled DPA-714, to visualize and quantify neuroinflammation in individuals with post-acute sequelae of SARS-CoV-2 (PASC) . The brain uptake of DPA-714 will be contrasted with healthy subjects.

This description comes directly from the study's public registry record.

Talk to the study team

April Riddle  ·  205-9961082  ·  RadiologyCRC@uabmc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

UABBirmingham, Alabama, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05656105